Bio-Rad Laboratories - BIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $436.67
  • Forecasted Upside: 55.81%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$280.25
▼ -3.63 (-1.28%)

This chart shows the closing price for BIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Rad Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIO

Analyst Price Target is $436.67
▲ +55.81% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is $436.67, with a high forecast of $550.00 and a low forecast of $315.00. The average price target represents a 55.81% upside from the last price of $280.25.

This chart shows the closing price for BIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Bio-Rad Laboratories. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$440.00 ➝ $315.00Low
5/8/2024UBS GroupLower TargetBuy ➝ Buy$420.00 ➝ $385.00Low
4/3/2024CitigroupDowngradeBuy ➝ Neutral$400.00 ➝ $365.00Low
2/16/2024UBS GroupBoost TargetBuy ➝ Buy$395.00 ➝ $420.00Low
2/16/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$484.00 ➝ $480.00Low
12/7/2023UBS GroupInitiated CoverageBuy$395.00Low
8/7/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$550.00 ➝ $525.00Low
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$522.00 ➝ $524.00Low
8/4/2023Credit Suisse GroupLower TargetOutperform ➝ Outperform$580.00 ➝ $550.00Low
6/16/2023Wells Fargo & CompanyInitiated CoverageOverweight$550.00Low
2/17/2023Royal Bank of CanadaBoost TargetOutperform$571.00 ➝ $579.00Low
2/17/2023Credit Suisse GroupBoost TargetOutperform$640.00 ➝ $680.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$565.00Low
10/28/2022Credit Suisse GroupLower TargetOutperform$715.00 ➝ $640.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$715.00Low
7/8/2022CitigroupLower TargetBuy$750.00 ➝ $700.00N/A
5/2/2022CitigroupLower Target$800.00 ➝ $750.00Medium
4/29/2022Jefferies Financial GroupReiterated RatingBuy$700.00High
2/11/2022CitigroupBoost Target$750.00 ➝ $800.00Low
1/28/2022CitigroupLower TargetBuy$915.00 ➝ $750.00High
7/30/2021Wells Fargo & CompanyBoost TargetOverweight$735.00 ➝ $930.00High
2/12/2021CitigroupBoost TargetBuy$675.00 ➝ $750.00Low
2/5/2021Jefferies Financial GroupBoost TargetBuy$660.00 ➝ $725.00Low
10/30/2020Smith Barney CitigroupBoost Target$625.00 ➝ $675.00Medium
10/30/2020Wells Fargo & CompanyBoost TargetOverweight$590.00 ➝ $650.00High
9/3/2020Jefferies Financial GroupReiterated RatingBuy ➝ Market Perform$666.00Medium
9/3/2020Wells Fargo & CompanyReiterated RatingBuy$590.00Medium
7/31/2020Wells Fargo & CompanyBoost TargetOverweight$525.00 ➝ $590.00High
7/31/2020CitigroupBoost TargetBuy$525.00 ➝ $625.00High
7/30/2020Wells Fargo & CompanyReiterated RatingBuyHigh
5/21/2020Wells Fargo & CompanyBoost TargetOverweight$495.00 ➝ $525.00Low
5/7/2020CitigroupBoost TargetBuy$480.00 ➝ $525.00Low
4/20/2020CitigroupBoost TargetBuy$425.00 ➝ $480.00Low
3/30/2020Wells Fargo & CompanyLower TargetOverweight$440.00 ➝ $385.00High
3/26/2020BarclaysLower TargetOverweight$435.00 ➝ $430.00Medium
3/20/2020CitigroupLower TargetBuy$450.00 ➝ $425.00High
3/3/2020CitigroupReiterated RatingBuy$450.00N/A
2/14/2020Wells Fargo & CompanyBoost TargetOverweight$430.00 ➝ $440.00High
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$430.00Low
1/6/2020CitigroupInitiated CoverageBuy$450.00High
8/20/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$400.00High
8/2/2019BarclaysBoost TargetOverweight$350.00 ➝ $380.00High
(Data available from 6/25/2019 forward)

News Sentiment Rating

1.33 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2023
  • 11 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/28/2023
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 24 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/26/2024
  • 15 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 13 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/26/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/26/2024
  • 24 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2024

Current Sentiment

  • 24 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Bio-Rad Laboratories logo
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More

Today's Range

Now: $280.25
Low: $279.74
High: $284.39

50 Day Range

MA: $284.85
Low: $268.26
High: $300.97

52 Week Range

Now: $280.25
Low: $261.59
High: $431.79

Volume

306,566 shs

Average Volume

223,101 shs

Market Capitalization

$7.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Rad Laboratories?

The following equities research analysts have issued reports on Bio-Rad Laboratories in the last year: Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., Royal Bank of Canada, StockNews.com, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BIO.

What is the current price target for Bio-Rad Laboratories?

6 Wall Street analysts have set twelve-month price targets for Bio-Rad Laboratories in the last year. Their average twelve-month price target is $436.67, suggesting a possible upside of 55.8%. Credit Suisse Group AG has the highest price target set, predicting BIO will reach $550.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $315.00 for Bio-Rad Laboratories in the next year.
View the latest price targets for BIO.

What is the current consensus analyst rating for Bio-Rad Laboratories?

Bio-Rad Laboratories currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BIO.

What other companies compete with Bio-Rad Laboratories?

How do I contact Bio-Rad Laboratories' investor relations team?

Bio-Rad Laboratories' physical mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company's listed phone number is (510) 724-7000 and its investor relations email address is [email protected]. The official website for Bio-Rad Laboratories is www.bio-rad.com. Learn More about contacing Bio-Rad Laboratories investor relations.